- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
More ▼
Key statistics
As of last trade Organovo Holdings Inc (ONVO:NAQ) traded at 0.5819, 5.80% above its 52-week low of 0.55, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.595 |
---|---|
High | 0.595 |
Low | 0.5606 |
Bid | 0.572 |
Offer | 0.5838 |
Previous close | 0.5859 |
Average volume | 306.39k |
---|---|
Shares outstanding | 14.37m |
Free float | 14.18m |
P/E (TTM) | -- |
Market cap | 8.42m USD |
EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 18:10 BST.
More ▼